Owing to its excellent response and acceptable toxicity profile, neoadjuvant chemotherapy with trastuzumab and pertuzumab is currently the preferred regimen for patients with HER2-positive breast cancer who are candidates for NAST. The gene discussed is ERBB2; the disease is breast carcinoma.